Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Sales and Divestitures (2021 - 2025)

Syndax Pharmaceuticals (SNDX) has 5 years of Gains from Sales and Divestitures data on record, last reported at $410707.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 380.39% year-over-year to $410707.0; the TTM value through Dec 2025 reached $410707.0, up 380.39%, while the annual FY2025 figure was $410707.0, 380.39% up from the prior year.
  • Gains from Sales and Divestitures reached $410707.0 in Q4 2025 per SNDX's latest filing, up from $85495.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $410707.0 in Q4 2025 and bottomed at $3750.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $55932.5, with a median of $9102.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 76.51% in 2023, then soared 839.3% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $5500.0 in 2021, then skyrocketed by 604.55% to $38750.0 in 2022, then crashed by 76.51% to $9102.0 in 2023, then skyrocketed by 839.3% to $85495.0 in 2024, then surged by 380.39% to $410707.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $410707.0 in Q4 2025, $85495.0 in Q4 2024, and $9102.0 in Q4 2023.